Patient with testosterone deficit syndrome and dyslipemia;Paciente con sdt y dislipemia

Archivos Espanoles de Urologia

Volumn 66, Issue 7, 2013, Pages 752-759

  Galarza, Ignacio Sola ^a   López, Borja López ^a   Abarca, Carlos Llorente ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Dyslipermia; Hypogonadism; Lipid; TDS

Indexed keywords

TESTOSTERONE;

ARTICLE; BLOOD; CASE REPORT; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; GENETICS; HUMAN; HYPOGONADISM; MALE; MIDDLE AGED;

DYSLIPIDEMIAS; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 84883723394     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74(1):1-12.
2. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001;166(2):569-74.
3. Montorsi P, Ravagnani PM, Galli S, Briganti A, Salonia A, Dehò F, Schulman C, Montorsi F. Association between erectile dysfunction and coronary artery disease: a case report study. J Sex Med. 2005;2(4):575-82.
4. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005; 174(3):827-34.
5. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci. 1999,18;892:25-44.
6. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S, Mohanty P. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med. 2008; 8(8):816-28
7. Lamarche B, Desroches S. Metabolic syndrome and effects of conjugated linoleic acid in obesity and lipoprotein disorders: the Québec experience. Am J Clin Nutr. 2004 Jun;79(6 Suppl):1149S-1152S.
8. Brewer HB Jr, Santamarina-Fojo S. Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Am J Cardiol. 2003, 21;92(4B):10K-16K.
9. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998, 12;97(18):1837-47.
10. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol. 2005; 1 (1): 39-59
11. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004; 89(10):4963-71.
12. Tinahones FJ, Garrido-Sánchez L, Murri M, García-fuentes E, Cardona F. Particular characteristics of the metabolic syndrome in patients with morbid obesity. Endocrinol Nutr. 201; 60(3):127-35.
13. Barbarroja N, López-Pedrera R, Mayas MD, García-Fuentes E, Garrido-Sánchez L, Macías-González M, El Bekay R, Vidal-Puig A, Tinahones FJ. The obese healthy paradox: is inflammation the answer? Biochem J. 2010 , 15;430(1):141-9.
14. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, El Bekay R, Tinahones FJ. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One. 2012;7(10):e48155.
15. Zimmet P, M M Alberti KG, Serrano Ríos M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Esp Cardiol. 2006;59(2):185.
16. Garcia-Cruz E, Piqueras M, Huguet J, Perez-Marquez M, Gosalbez D, Peri L, Izquierdo L, Luque P, Ribal MJ, Alcaraz A. Hypertension, dyslipidemia and overweight are related to lower testosterone levels in a cohort of men undergoing prostate biopsy. Int J Impot Res. 2012;24(3):110-3.
17. Cardiology organizations issue guidelines on Viagra use. Harv Heart Lett. 199;9(5):6.
18. Sniderman AD, Thanassoulis G. Do statins lower testosterone and does it matter? BMC Med. 2013, 28;11:58.
19. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013, 28;11:57.
20. La Vignera S, Condorelli RA, Vicari E, Calogero AE. Statins and erectile dysfunction: a critical summary of current evidence. J Androl. 2012; 33(4):552-8.
21. Gokce M, Gülpinar Ö, Öztürk E, Güleç S, Yaman Ö. Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study. Int Urol Nephrol. 2012;44(3):683-7.
22. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131-43. Review.
23. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92(10):3844-53. Epub 2007 Jul 17.